Back to top
more

Neogen (NEOG)

(Delayed Data from NSDQ)

$4.68 USD

4.68
4,712,984

+0.02 (0.43%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $4.68 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Neogen (NEOG) Launches Genomic Test for Beef-on-Dairy Calves

by Zacks Equity Research

Neogen's (NEOG) new Igenity BeefXDairy test is an additional tool, enabling producers to gather crucial data they need to advance and grow their operations effectively and sustainably.

Zacks Equity Research

Neogen (NEOG) Introduces 2 Assays for Histamine Detection

by Zacks Equity Research

Neogen (NEOG) launches Reveal for Histamine and Reveal Q+ for Histamine assays for the detection of Histamine.

Zacks Equity Research

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG) owing to strong performance across its Animal Safety and Food Safety segments.

Zacks Equity Research

Neogen (NEOG) New Buyouts Aid Growth Amid Rise in Expenses

by Zacks Equity Research

Neogen's (NEOG) performance of the Food Safety business is strong, driven by several long-term secular tailwinds.

Zacks Equity Research

Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.

Zacks Equity Research

Neogen (NEOG) Q3 Earnings Beat Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of 200% and 1.60%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Equity Research

Neogen (NEOG) Receives New Label Claims for Viroxide Super

by Zacks Equity Research

Neogen's (NEOG) Viroxide Super active constituents are potassium peroxymonosulfate and sodium chloride, which have been verified effective against multiple industry-relevant bacteria and viruses.

Zacks Equity Research

Neogen (NEOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Neogen (NEOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Earnings Season Could Be Great for Neogen (NEOG)

by Zacks Equity Research

Neogen (NEOG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Will Healthy Top-Line Growth Aid Jabil's (JBL) Q2 Earnings?

by Zacks Equity Research

Jabil (JBL) is likely to witness top-line expansion backed by the company's continuous innovation approach, favorable demand trends and excellent operational execution.

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Equity Research

Neogen's (NEOG) New Launches Aid, Margin Pressure Stays

by Zacks Equity Research

Neogen (NEOG) continues to see rising revenues from the Food Safety business.

Zacks Equity Research

ICU Medical (ICUI) Beats Q4 Earnings Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 6.67% and 0.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.

Zacks Equity Research

Henry Schein (HSIC) Q4 Earnings In Line, Gross Margin Up

by Zacks Equity Research

Growth in Technology and Value-added Services and the Medical segment drove Henry Schein's (HSIC) Q4 revenues.

Zacks Equity Research

Bruker (BRKR) Q4 Earnings Beat Estimates, Margins Increase

by Zacks Equity Research

Robust performance across most of the geographies and operating segments drove Bruker's (BRKR) Q4 revenues.

Zacks Equity Research

Phibro (PAHC) Q2 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Growing uptake of MFAs, dairy products and vaccines contributed to Phibro's (PAHC) Q2 revenues.

Zacks Equity Research

STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y

by Zacks Equity Research

Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.

Zacks Equity Research

Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.

Zacks Equity Research

QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.

Zacks Equity Research

What's in the Cards for Medtronic (MDT) in Q3 Earnings?

by Zacks Equity Research

Severe currency headwinds are expected to have affected Medtronic's (MDT) profitability in fiscal Q3.

Zacks Equity Research

IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases

by Zacks Equity Research

IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.

Zacks Equity Research

Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.

Zacks Equity Research

CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales

by Zacks Equity Research

CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.